243 related articles for article (PubMed ID: 16585388)
1. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
3. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
Morimitsu LK; Fusaro AS; Sanchez VH; Hagemann CC; Bertini AM; Dib SA
Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
6. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
7. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.
Pratte KA; Barón AE; Ogden LG; Hassell KL; Rewers M; Hokanson JE
J Diabetes Complications; 2009; 23(6):387-93. PubMed ID: 18768333
[TBL] [Abstract][Full Text] [Related]
9. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.
Ingelsson E; Pencina MJ; Tofler GH; Benjamin EJ; Lanier KJ; Jacques PF; Fox CS; Meigs JB; Levy D; Larson MG; Selhub J; D'Agostino RB; Wang TJ; Vasan RS
Circulation; 2007 Aug; 116(9):984-92. PubMed ID: 17698726
[TBL] [Abstract][Full Text] [Related]
10. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Festa A; D'Agostino R; Tracy RP; Haffner SM;
Diabetes; 2002 Apr; 51(4):1131-7. PubMed ID: 11916936
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
13. Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.
Jae SY; Heffernan KS; Lee MK; Fernhall B; Park WH
Am J Cardiol; 2008 Sep; 102(6):700-3. PubMed ID: 18773991
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study.
Donahue RP; Rejman K; Rafalson LB; Dmochowski J; Stranges S; Trevisan M
Diabetes Care; 2007 Feb; 30(2):354-9. PubMed ID: 17259507
[TBL] [Abstract][Full Text] [Related]
16. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
Thromb Haemost; 1999 Mar; 81(3):367-72. PubMed ID: 10102462
[TBL] [Abstract][Full Text] [Related]
17. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
18. Relationship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance.
Heldgaard PE; Sidelmann JJ; Hindsberger C; Olivarius Nde F; Henriksen JE; Gram J
Diabet Med; 2006 Aug; 23(8):887-93. PubMed ID: 16911627
[TBL] [Abstract][Full Text] [Related]
19. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
